{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T20:18:07Z","timestamp":1767212287272,"version":"3.48.0"},"reference-count":47,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T00:00:00Z","timestamp":1662595200000},"content-version":"unspecified","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002842","name":"Chiang Mai University","doi-asserted-by":"publisher","award":["ORA2564\/635"],"award-info":[{"award-number":["ORA2564\/635"]}],"id":[{"id":"10.13039\/501100002842","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2022,8,14]]},"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Therapeutic recommendations for hidradenitis suppurativa (HS) have recently shifted towards non-invasive pharmacological options. Recent evidence has shown promising efficacy for specific treatments. However, data regarding the comparative efficacy of these treatments in patients with HS are still limited. Therefore, we plan to conduct a systematic review and network meta-analysis (NMA) to summarise the benefits and harms of different pharmacological interventions for treating people living with HS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>We will search electronic databases, including Medline, Embase, PubMed, Web of Science, Scopus, CINAHL and Cochrane Library beginning from their inception dates with no language restrictions. A grey literature search will be performed to supplement the electronic databases. Both randomised trials and non-randomised studies using validated measurement tools that investigated the benefits and harms of pharmacological interventions among people living with HS will be included. The predefined primary outcomes will include treatment responses that reflect the patient\u2019s perspective and all-cause discontinuation. Screening, selection, extraction, assessment of the risk of bias and analysis of the strength of the evidence will be performed independently by a pair of reviewers. A two-step approach of traditional pairwise and NMA will be performed. Based on a random-effects model, standardised weighted mean differences and ORs with corresponding 95% CIs will be pooled as effect estimates for the continuous and categorical endpoints, respectively. Statistical and methodological heterogeneities will be assessed. Preplanned subgroup analyses and univariate meta-regression will be conducted to quantify the potential sources of heterogeneity. Evidence-based synthesis will be based on the magnitudes of effect size, evidence certainty and the surface under the cumulative ranking curve values.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Ethical approval is not required because this study is based on existing published data. These findings will be disseminated through scientific meetings and publications in peer-reviewed journals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration number<\/jats:title>\n                    <jats:p>CRD42022302795.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2022-062351","type":"journal-article","created":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T11:39:27Z","timestamp":1662637167000},"page":"e062351","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacological interventions for hidradenitis suppurativa: a protocol for systematic review and network meta-analysis of randomised trials and non-randomised studies"],"prefix":"10.1136","volume":"12","author":[{"given":"Naritthorn","family":"Aroonsakul","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8543-6254","authenticated-orcid":false,"given":"Phichayut","family":"Phinyo","sequence":"additional","affiliation":[{"name":"Center for Clinical Epidemiology and Clinical Statistics, Faculty of Medicine, Chiang Mai University, Suthep, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lalita","family":"Lumkul","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nutcha","family":"Jarupanich","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacek","family":"Szepietowski","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroclaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mati","family":"Chuamanochan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Chiang Mai University, Muang, Thailand"},{"name":"Pharmacoepidemiology and Statistics Research Center (PESRC), Chiang Mai University, Chiang Mai, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1100-7171","authenticated-orcid":false,"given":"Surapon","family":"Nochaiwong","sequence":"additional","affiliation":[{"name":"Pharmacoepidemiology and Statistics Research Center (PESRC), Chiang Mai University, Chiang Mai, Thailand"},{"name":"Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,9,8]]},"reference":[{"key":"2025121410060745000_12.9.e062351.1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.472"},{"key":"2025121410060745000_12.9.e062351.2","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jaad.2019.02.067","article-title":"North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian hidradenitis suppurativa foundations: Part I: diagnosis, evaluation, and the use of complementary and procedural management","volume":"81","author":"Alikhan","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2025121410060745000_12.9.e062351.3","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1001\/jama.2017.16691","article-title":"Hidradenitis suppurativa: advances in diagnosis and treatment","volume":"318","author":"Saunte","year":"2017","journal-title":"JAMA"},{"key":"2025121410060745000_12.9.e062351.4","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.12788\/j.sder.0093","article-title":"Recognizing and managing comorbidities and complications in hidradenitis suppurativa","volume":"33","author":"Menter","year":"2014","journal-title":"Semin Cutan Med Surg"},{"key":"2025121410060745000_12.9.e062351.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.09.012"},{"key":"2025121410060745000_12.9.e062351.6","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jaad.2021.06.843","article-title":"Prevalence of depression among children, adolescents, and adults with hidradenitis suppurativa","volume":"86","author":"Wright","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2025121410060745000_12.9.e062351.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.09.008"},{"key":"2025121410060745000_12.9.e062351.8","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/bjd.14922","article-title":"A pilot study of unemployment in patients with hidradenitis suppurativa in Denmark","volume":"176","author":"Theut Riis","year":"2017","journal-title":"Br J Dermatol"},{"key":"2025121410060745000_12.9.e062351.9","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/j.jaad.2015.07.044","article-title":"Recurrence of hidradenitis suppurativa after surgical management: a systematic review and meta-analysis","volume":"73","author":"Mehdizadeh","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"2025121410060745000_12.9.e062351.10","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1111\/bjd.17151","article-title":"Cost-savings of adalimumab in hidradenitis suppurativa: a retrospective analysis of a real-world cohort","volume":"180","author":"Argyropoulou","year":"2019","journal-title":"Br J Dermatol"},{"key":"2025121410060745000_12.9.e062351.11","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1159\/000503605","article-title":"A comparison of international management guidelines for hidradenitis suppurativa","volume":"237","author":"Hendricks","year":"2021","journal-title":"Dermatology"},{"key":"2025121410060745000_12.9.e062351.12","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jaad.2019.02.068","article-title":"North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management","volume":"81","author":"Alikhan","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2025121410060745000_12.9.e062351.13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4362.1983.tb02150.x"},{"key":"2025121410060745000_12.9.e062351.14","doi-asserted-by":"publisher","DOI":"10.2165\/11631880-000000000-00000"},{"key":"2025121410060745000_12.9.e062351.15","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/j.jaad.2015.07.049","article-title":"Scientific evidence for the use of current traditional systemic therapies in patients with hidradenitis suppurativa","volume":"73","author":"Alhusayen","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"2025121410060745000_12.9.e062351.16","doi-asserted-by":"crossref","unstructured":"Gupta AK , Shear NH , Piguet V . Efficacy of non-surgical monotherapies for hidradenitis suppurativa: a systematic review and network meta-analyses of randomized trials. J Dermatolog Treat 2021:1\u201332.doi:10.1080\/09546634.2021.1927949","DOI":"10.1080\/09546634.2021.1927949"},{"key":"2025121410060745000_12.9.e062351.17","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa","volume":"375","author":"Kimball","year":"2016","journal-title":"N Engl J Med"},{"key":"2025121410060745000_12.9.e062351.18","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1001\/jamadermatol.2015.3903","article-title":"Safety and efficacy of Anakinra in severe hidradenitis suppurativa: a randomized clinical trial","volume":"152","author":"Tzanetakou","year":"2016","journal-title":"JAMA Dermatol"},{"key":"2025121410060745000_12.9.e062351.19","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1177\/12034754211035667","article-title":"Treatment outcomes of IL-17 inhibitors in hidradenitis suppurativa: a systematic review","volume":"26","author":"Kashetsky","year":"2022","journal-title":"J Cutan Med Surg"},{"key":"2025121410060745000_12.9.e062351.20","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jaad.2018.06.046","article-title":"Apremilast for moderate hidradenitis suppurativa: results of a randomized controlled trial","volume":"80","author":"Vossen","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2025121410060745000_12.9.e062351.21","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s40257-020-00537-9","article-title":"Botulinum toxin type B for hidradenitis suppurativa: a randomised, double-blind, placebo-controlled pilot study","volume":"21","author":"Grimstad","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"2025121410060745000_12.9.e062351.22","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s13555-021-00674-x","article-title":"Dapsone in hidradenitis suppurativa: a systematic review","volume":"12","author":"Rabindranathnambi","year":"2022","journal-title":"Dermatol Ther"},{"key":"2025121410060745000_12.9.e062351.23","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2020.591580","article-title":"The efficacy and effectiveness of Non-ablative light-based devices in hidradenitis suppurativa: a systematic review and meta-analysis","volume":"7","author":"Jfri","year":"2020","journal-title":"Front Med"},{"key":"2025121410060745000_12.9.e062351.24","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1001\/jamadermatol.2021.2905","article-title":"Efficacy and safety of Bimekizumab in moderate to severe hidradenitis suppurativa: a phase 2, double-blind, placebo-controlled randomized clinical trial","volume":"157","author":"Glatt","year":"2021","journal-title":"JAMA Dermatol"},{"key":"2025121410060745000_12.9.e062351.25","unstructured":"Higgins JPT , Thomas J , Chandler J . Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). In: Cochrane, 2021."},{"key":"2025121410060745000_12.9.e062351.26","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"349","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"2025121410060745000_12.9.e062351.27","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.m2864","article-title":"When to replicate systematic reviews of interventions: consensus checklist","volume":"9","author":"Tugwell","year":"2020","journal-title":"BMJ"},{"key":"2025121410060745000_12.9.e062351.28","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4"},{"key":"2025121410060745000_12.9.e062351.29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"key":"2025121410060745000_12.9.e062351.30","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919"},{"key":"2025121410060745000_12.9.e062351.31","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2385"},{"key":"2025121410060745000_12.9.e062351.32","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-25"},{"key":"2025121410060745000_12.9.e062351.33","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-11-159"},{"key":"2025121410060745000_12.9.e062351.34","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629"},{"key":"2025121410060745000_12.9.e062351.35","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies","volume":"3","author":"Higgins","year":"2012","journal-title":"Res Synth Methods"},{"key":"2025121410060745000_12.9.e062351.36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0076654"},{"key":"2025121410060745000_12.9.e062351.37","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d549"},{"key":"2025121410060745000_12.9.e062351.38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003082"},{"key":"2025121410060745000_12.9.e062351.39","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g5630"},{"key":"2025121410060745000_12.9.e062351.40","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jaip.2021.10.022","article-title":"Impact of pharmacological treatments for chronic spontaneous urticaria with an inadequate response to H1-antihistamines on health-related quality of life: a systematic review and network meta-analysis","volume":"10","author":"Nochaiwong","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025121410060745000_12.9.e062351.41","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1001\/jamadermatol.2021.3237","article-title":"Evaluation of pharmacologic treatments for H1 Antihistamine-Refractory chronic spontaneous urticaria: a systematic review and network meta-analysis","volume":"157","author":"Nochaiwong","year":"2021","journal-title":"JAMA Dermatol"},{"key":"2025121410060745000_12.9.e062351.42","doi-asserted-by":"publisher","DOI":"10.1080\/03610911003650383"},{"key":"2025121410060745000_12.9.e062351.43","unstructured":"Cohen J . Statistical power analysis for the behavioral sciences. 2nd ed. New York: Routledge, 1988."},{"key":"2025121410060745000_12.9.e062351.44","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"2025121410060745000_12.9.e062351.45","doi-asserted-by":"crossref","DOI":"10.1177\/20406223211055920","article-title":"New perspectives on the treatment of hidradenitis suppurativa","volume":"12","author":"Amat-Samaranch","year":"2021","journal-title":"Ther Adv Chronic Dis"},{"key":"2025121410060745000_12.9.e062351.46","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14010044","article-title":"Hidradenitis suppurativa and comorbid disorder biomarkers, druggable genes, new drugs and drug Repurposing-A molecular meta-analysis","volume":"14","author":"Zouboulis","year":"2021","journal-title":"Pharmaceutics"},{"key":"2025121410060745000_12.9.e062351.47","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/bjd.15255","article-title":"Nice approval of adalimumab for moderate-to-severe hidradenitis suppurativa: the end of the beginning for hidradenitis suppurativa therapeutics?","volume":"176","author":"Ingram","year":"2017","journal-title":"Br J Dermatol"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2022-062351","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T18:06:16Z","timestamp":1765735576000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2022-062351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":47,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9,8]]},"published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.1136\/bmjopen-2022-062351"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2022-062351","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2022,9]]}}}